GH Guardant Health, Inc.
GH Guardant Health, Inc.
Healthcare · Diagnostics & Research
Market read
Scan convergence 2 scans as of 2026-10-16 2 neutral converging
POC $98.41 · VWAP $120.20 · +31.9% vs 12m avg buyer
Insiders selling 0 buy / 1 sell · Form 4, 90d $10.8M sold last open-market sell Freeman Chris
Cluster CTO, Director + 3 others sold $3.3M, Sep 14–17
Coverage
1 watchlist
GH Price Structure
Loading timeframes…
Peers
Every watchlist GH belongs to, members best 30-day change first — GH highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@healthcare
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Reported the quarter ending 2026-06-30: revenue $335M, diluted EPS -$0.90, net income -$120M (SEC filing). Across the print the stock moved +12.4% (close before → first close after).
full note →Against street estimates
How GH's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about GH from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 28 days ago · Sep 19
GH research tape
97 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.